Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and fatal neurodegenerative disease characterized by progressive weakness involving limb, bulbar, and respiratory muscles.There is currently no information suggesting how COVID-19 affects patients diagnosed with amyotrophic lateral sclerosis (ALS). This is especially important as respiratory compromise is common in ALS patients and can complicate the clinical course as COVID-19 could lead to respiratory failure and need for intubation. We intend that this registry will guide our understanding of how COVID-19 affects patients with ALS.

The purpose of this registry is to assess the incidence and prevalence of COVID-19 in ALS patients, the effect of COVID-19 on ALS disease trajectory, and the impact, if any, of edaravone, riluzole and other concomitant medication used in ALS like Albuterol and dextromethorphan/quinidine (Nuedexta) on these parameters. COVID-19 incidence and prevalence in the ALS population will be assessed through outcomes reporting ranging from recovered infections to patient death reported in a patient facing registry.

Inclusion Criteria:

• Diagnosis of ALS and

• A confirmed COVID-19 infection determined by:

  1. positive SARS-CoV-2 viral RNA PCR test and/or
  2. positive serology antibody testing for SARS-CoV-2

Exclusion Criteria:

• No ALS diagnosis
• No confirmed COVID-19 infection

Our study population consists of qualifying cases of patients with ALS who have had a laboratory confirmed COVID-19 infection.